Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoichiro YoshidaTakeshi YamadaHirohiko KamiyamaChihiro KosugiKeiichiro IshibashiHiroshi YoshidaHideyuki IshidaSatoru YamaguchiHidekazu KuramochiAtsuko FukazawaHiromichi SonodaKazuhiko YoshimatsuAkihisa MatsudaSuguru HasegawaKazuhiro SakamotoToshiaki OtsukaKeiji Kodanull nullPublished in: International journal of clinical oncology (2020)
This study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC.